

# Apple Health PDL Drug Class Motions

# Analgesics : Opioid Agonists - Long Acting

---

## ▶ Recommendation:

- ▶ All products in the Analgesics : Opioid Agonists - Long Acting drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Analgesics : Opioid Agonists - Long Acting

---

▶ **Motion:** I move that all products in the Analgesics : Opioid Agonists - Long Acting drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion: Lee**

▶ **2<sup>nd</sup>: Brown**

# Antiemetics / Antivertigo Agents :

---

- ▶ 5-HT<sub>3</sub> Receptor Antagonists
- ▶ Substance P/Neurokinin 1 (NK1) Receptor Antagonists
- ▶ Substance P/Neurokinin 1 Receptor Antagonist Combinations

# Antiemetics / Antivertigo Agents :

---

## ▶ Recommendation:

- ▶ All products listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Antiemetics / Antivertigo Agents :

---

**Motion:** I move that all products in the drug classes listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Flatebo**
- ▶ **2<sup>nd</sup>: Corsilles**

# Antihypertensives :

---

- ▶ Direct Renin Inhibitor Combinations
- ▶ Direct Renin Inhibitor
- ▶ Neprilysin Inhib (ARNI)-Angiotensin II Recept Antag Combinations

# Antihypertensives :

---

## ▶ Recommendation:

- ▶ All products listed on slide 7 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.



# Antihypertensives :

---

**Motion:** I move that all products in the drug classes listed on slide 7 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Storhaug**

# Antivirals : Hepatitis C Agents- Direct Acting Antivirals

---

## ▶ Recommendation:

- ▶ All products in the Antivirals : Hepatitis C Agents drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ Non-preferred products in this class may be considered medically necessary when the preferred agent is not indicated.

# Antivirals : Hepatitis C Agents- Direct Acting Antivirals

---

▶ **Motion:** I move that all products in the Antivirals : Hepatitis C Agents- Direct acting antivirals drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. Non-preferred products in this class may be considered medically necessary when the preferred agent is not indicated.

▶ **Motion: Corsilles**

▶ **2<sup>nd</sup>: Schwilke**

# Antivirals :

---

- ▶ HIV
- ▶ HIV Combinations

# Antivirals :

---

## ▶ Recommendation:

- ▶ All products listed on slide 12 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ Non-preferred products in this class may be authorized if the patient meets the criteria outlined in the clinical policy.

# Antivirals :

---

**Motion:** I move that all products in the drug classes listed on slide 12 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. Non-preferred products in this class may be authorized if the patient meets the criteria outlined in the clinical policy.

▶ **Motion: DEFERRED**

▶ **2<sup>nd</sup>:**

# Endocrine and Metabolic Agents :

---

- ▶ Androgens – Testosterone
- ▶ Bone Density Regulators - Sclerostin Inhibitors

# Endocrine and Metabolic Agents :

---

## ▶ Recommendation:

- ▶ All products listed on slide 15 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.



# Endocrine and Metabolic Agents :

---

**Motion:** I move that all products in the drug classes listed on slide 15 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Corsilles**
- ▶ **2<sup>nd</sup>: Lee**

# Migraine Agents :

---

- ▶ Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists
- ▶ Selective Serotonin Agonists 5-HT(1)

# Migraine Agents :

---

## ▶ Recommendation:

- ▶ All products listed on slide 18 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Migraine Agents :

---

**Motion:** I move that all products in the drug classes listed on slide 18 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion: DEFERRED**

▶ **2<sup>nd</sup>:**

# Pulmonary Hypertension Agents :

---

- ▶ Endothelin Receptor Antagonists
- ▶ Prostacyclin Receptor Agonists
- ▶ Prostaglandin Vasodilators
- ▶ SGC Stimulator
- ▶ Phosphodiesterase Inhibitors (PDEI)

# Pulmonary Hypertension Agents :

---

## ▶ Recommendation:

- ▶ All products listed on slide 21 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Pulmonary Hypertension Agents :

---

**Motion:** I move that all products in the drug classes listed on slide 21 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Corsilles**